Kerri Fitzgerald

DocwireNews

A real-world study presented at the 2020 ASH Annual Meeting observed no significant survival differences in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were treated with bendamustine plus rituximab (BR) versus rituximab plus gemcitabine and oxaliplatin (R-GemOx).Researchers retrospectively analyzed real-world data from the Surveillance, Epidemiology, and End Results registry as well as linked Medicare enrollment data and insurance claims. They identified patients with a cancer diagnosis between 2004 and 2016 and included 3,606 patients aged &gt;65 years who were diagnosed with DLBCL not otherwise specified and received second-line BR (n=308) or R-GemOx (n=131) alone. Patients with evidence of prior hospice care were excluded.Median follow-up was 12.42 months (range, 4.78-28.41 months) in the BR group and 7.72 months (range, 3.02-21.14 months) in the R-GemOx group. Patients treated with R-GemOx were more likely to be younger (median age, 77 years vs. 80 years) and male (61.1% vs. 45.8%). A similar proportion of patients were primary refractory in each treatment group (BR, 20.8%; R-GemOx, 21.4%; P=0.99).The unadjusted median duration of second-line treatment was 11.4 weeks (range, 4.29-20.04 weeks) with BR and 8.14 weeks (range, 4.07-14.71 weeks) with R-GemOx. Median overall survival (OS) was 16.39 months in the BR group (95% confidence interval [CI], 13.01-19.48) and 8.74 months in the R-GemOx group (95% CI, 7.00-12.98). After adjusting for covariates, median OS was 16.39 months (95% CI, 12.88-19.48) and 9.26 months (95% CI, 7.10-14.36), respectively. The hazard ratio (HR) for adjusted OS in the second line of therapy was 1.24 (95% CI, 0.97-1.58) for R-GemOx compared with BR. After propensity score adjustment, the HR for OS in the third line of therapy was 0.996 (95% CI, 0.70-1.42) for R-GemOx compared with BR.The study is limited by the assumption that all important variables have been accounted for in the propensity scoring and by the use of database information, which may not be generalizable to a wider patient population.&ldquo;In the absence of comparative data from randomized, controlled trials, this real-world data analysis demonstrates similar real-world effectiveness of the two regimens in relapsed/refractory DLBCL,&rdquo; the researchers concluded.ReferenceCastro F, Surinach A, Launonen A, et al. Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Abstract 3042. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Which of These Treatment Combinations Extend Survival for DLBCL?

ASH Annual Meeting 2020

A real-world study presented at the 2020 ASH Annual Meeting observed no significant survival differences in patients with relapsed/refractory diffuse large B-cell lymphoma ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe